- Home
- WDI vs KALV Comparison
WDI vs KALV Comparison
Compare WDI & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDI
- KALV
- Stock Information
- Founded
- WDI 2021
- KALV N/A
- Country
- WDI United States
- KALV United States
- Employees
- WDI N/A
- KALV N/A
- Industry
- WDI Trusts Except Educational Religious and Charitable
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- WDI Finance
- KALV Health Care
- Exchange
- WDI Nasdaq
- KALV Nasdaq
- Market Cap
- WDI 775.8M
- KALV 796.4M
- IPO Year
- WDI N/A
- KALV N/A
- Fundamental
- Price
- WDI $15.11
- KALV $15.78
- Analyst Decision
- WDI
- KALV Strong Buy
- Analyst Count
- WDI 0
- KALV 9
- Target Price
- WDI N/A
- KALV $26.29
- AVG Volume (30 Days)
- WDI 192.6K
- KALV 734.1K
- Earning Date
- WDI 01-01-0001
- KALV 09-09-2025
- Dividend Yield
- WDI 11.80%
- KALV N/A
- EPS Growth
- WDI N/A
- KALV N/A
- EPS
- WDI 1.12
- KALV N/A
- Revenue
- WDI N/A
- KALV N/A
- Revenue This Year
- WDI N/A
- KALV N/A
- Revenue Next Year
- WDI N/A
- KALV $221.95
- P/E Ratio
- WDI $12.82
- KALV N/A
- Revenue Growth
- WDI N/A
- KALV N/A
- 52 Week Low
- WDI $12.16
- KALV $7.30
- 52 Week High
- WDI $14.69
- KALV $16.32
- Technical
- Relative Strength Index (RSI)
- WDI 59.14
- KALV 70.52
- Support Level
- WDI $14.97
- KALV $13.72
- Resistance Level
- WDI $15.18
- KALV $13.96
- Average True Range (ATR)
- WDI 0.09
- KALV 0.66
- MACD
- WDI 0.00
- KALV 0.33
- Stochastic Oscillator
- WDI 70.25
- KALV 91.45
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.